

A. PATIENT INFORMATION				
Primary Patient ID		Secondary Patient ID		
DOB (DD/MM/YYYY)	Biological Sex F M	Race/Ethnicity		
B. ORDERING PHYSICIAN INFORMATION				
Distributor		Ordering Physician (full legal name)		Phone
Facility Name		Tempus Account #	Email (required for report delivery)	Fax
Facility Address (Street, Unit)		City	Postal Code	Country
Additional person to be copied				
Name		Email/Fax	Facility Name	
C. TESTING OPTIONS				
Common test combinations	Test descriptions	Specimen required	Optional add-on tests (select all that apply):	
<b>xT (DNA) &amp; xR (RNA): Solid Tumor/Normal</b>	xT: 648-gene DNA sequencing test with normal match; xR: whole transcriptome RNA sequencing test.	FFPE Tissue; Normal: Blood or Saliva	<b>xT Solid Tumor, xR LDT FFPE Tissue</b>  PD-L1 IHC: 22C3 <small>DEFAULT</small> 28-8 SP142 SP263 MMR IHC HRD* Tumor Origin (RNA)	<b>xT Normal Blood or Saliva</b>  DPYD UGT1A1
Add xF liquid biopsy at time of order, based on the following: I believe it is medically necessary to order a liquid biopsy test concurrently with a solid tumor tissue test because of one or more of the following reasons: (a) guidelines support the use of testing in this disease state; (b) turnaround time for tissue result may delay a treatment decision for my patient; (c) the tissue is at risk to fail (e.g. small tissue, archived tissue) and I may not have a timely result to make a treatment decision for my patient; (d) genomic heterogeneity may cause the patient's available tissue to not be completely representative, and I want to make sure I have a complete mutation profile.				
If I have not already ordered an xF test above, I opt to convert my xT solid tumor order to an xF liquid biopsy test if necessary: By converting immediately <b>OR</b> After an additional tissue request is attempted				
<b>xT (DNA) &amp; xR (RNA): Solid Tumor</b>	xT: 648-gene DNA sequencing test; xR: whole transcriptome RNA sequencing test.	FFPE Tissue		
<b>xE (DNA) &amp; xR (RNA): Solid Tumor/Normal</b>	xE: over 19,000-gene whole exome DNA sequencing test with normal match; xR: whole transcriptome RNA sequencing test.	FFPE Tissue; Normal: Blood or Saliva		
Individual test options				
<b>xR (RNA Only): Solid Tumor</b>	Whole transcriptome RNA sequencing test.	FFPE Tissue		
<b>xT (DNA Only): Solid Tumor</b>	648-gene DNA sequencing test.	FFPE Tissue	* Normal sample is required for ovarian or breast cancers.	
<b>xF (Liquid Biopsy): OR xF+ (Liquid Biopsy):</b>	xF: 105-gene or xF+: 523-gene liquid biopsy test for solid tumors.	Blood (Streck)		
<b>xE (DNA Only): Solid Tumor/Normal</b>	Over 19,000-gene whole exome DNA sequencing test with normal match.	FFPE Tissue; Normal: Blood or Saliva		
D. SPECIMEN RETRIEVAL <small>See Tempus' specimen guidelines for collection instructions and further details.</small>				
FFPE Tissue				
<b>Option 1:</b> Specific specimen requested	<b>Option 2:</b> Let the submitting pathologist choose specimen	<b>Option 3:</b> Biopsy to be scheduled for:	Pathology Lab (Name, City)	
			Case Number	Block #
			Date of Collection	
Blood				
Sample previously submitted		Send saliva kit to patient		
Date of Collection:		Date of Collection:		
E. CURRENT DIAGNOSIS				
Breast	NSCLC	Pancreatic	Other:	Primary ICD-10 Codes (C & D codes only)
Colorectal	Ovarian	Prostate		Stage I III Other: II IV
Disease Status (select all that apply): Metastatic Relapse Other: Refractory Recurrent			Has the patient had any type of transplant? No Yes —Type:	
F. PHYSICIAN SIGNATURE AND CONSENT				
I certify that the patient has received an explanation of the purpose, risks, and benefits of the ordered test(s). My signature below certifies medical necessity of the test(s) (including that the test results will inform the treatment plan) and further certifies that I am authorized to order the test(s) and that the patient has provided informed consent that meets the requirements of applicable law for Tempus or its reference lab to: (a) collect and use the patient's samples (including genetic material) and health information and perform the ordered test(s); (b) obtain, receive, and release health information (including test results) as necessary for reimbursement or the processing of insurance claims (if applicable); and (c) collect, use, and retain samples and information obtained from the patient, all in accordance with the Tempus Consent to Genomic Testing form signed by the patient.			Ordering Physician Signature	
			Printed Name (full legal name)	